A Randomised, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Efficacy of Recombinant Human Beta Defensin 2 (rHuB[beta]D2 cream) in the Treatment of Staphylococcus aureus and other Infections in the Skin of Patients with Atopic Dermatitis

Trial Profile

A Randomised, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Efficacy of Recombinant Human Beta Defensin 2 (rHuB[beta]D2 cream) in the Treatment of Staphylococcus aureus and other Infections in the Skin of Patients with Atopic Dermatitis

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Beta defensin 2 (Primary)
  • Indications Atopic dermatitis; Skin infections; Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Planton
  • Most Recent Events

    • 27 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top